Windtree Therapeutics to Embrace Cryptocurrency for Payments and Asset Management
WARRINGTON, Pa. – Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology firm dedicated to generating revenue while advancing both early and late-stage innovative therapies for critical health issues, has announced that its Board of Directors has approved the establishment of a cryptocurrency policy. This new policy will enable the Company to accept cryptocurrency as a payment method and to hold it as an asset. The move aligns with the growing trend of digital commerce, where a vast number of individuals are now holding cryptocurrencies. Payments made to Windtree through cryptocurrency could potentially be retained long-term as a strategic asset. “Windtree is implementing a new corporate strategy aimed at generating revenue, and we are currently in talks with various groups that specialize in Bitcoin and other cryptocurrencies as potential payment options. These entities are keen on developing a treasury strategy alongside Windtree and its diverse operational base. Our Company is also positioned to hold cryptocurrency as an asset,” stated Jed Latkin, CEO of Windtree. “Our Board is supportive of this initiative as we work towards finalizing our cryptocurrency policy in the near future.”
Overview of Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is a biotechnology company focused on achieving revenue generation while advancing innovative therapies for critical conditions and diseases at various stages of development. Among its product candidates, Windtree is developing istaroxime, a Phase 2 candidate designed to activate SERCA2a for the treatment of acute heart failure and related cardiogenic shock. Additionally, the company is working on preclinical SERCA2a activators for heart failure, as well as precision aPKCi inhibitors aimed at addressing both rare and widespread oncology applications. Windtree also operates under a licensing business model, with existing partnership out-licenses.
Forward-Looking Statements
This press release contains statements that may be considered forward-looking within the context of The Private Securities Litigation Reform Act of 1995. The Company may use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or similar phrases to indicate uncertainty regarding future events or outcomes. These statements are based on information available to the Company at the time of this press release and are subject to various important factors, risks, and uncertainties that could cause actual outcomes to differ significantly from the Company’s current expectations. Examples of such risks and uncertainties include the Company’s ability to acquire revenue-generating subsidiaries, market reactions to potential acquisitions, the ability to secure additional capital as required, risks associated with the success of clinical development programs for istaroxime and other candidates, and challenges in accessing debt or equity markets. Furthermore, the Company faces potential delays in clinical trials, rigorous regulatory requirements, and risks related to the geopolitical environment that may impact operations. These and other risks are detailed in the Company’s periodic reports, such as its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, filed with the Securities and Exchange Commission. Any forward-looking statements made in this press release are only valid as of the date of the release, and the Company assumes no obligation to update them based on new information or future events.
